Netflix Stock Is FINALLY A Buy!
1 extracted signal · 0 resolved · 1 still active
The Patient Investor16 Jul 2026, 21:29 UTC
AI-generated source summary
Netflix reported a slight miss on revenue and EPS for the past quarter, with revenue at $12.56 billion versus an estimate of $12.59 billion, and EPS at $0.80 versus an estimated $0.79. Despite these results, the company expects its advertising revenue to double year-over-year to $3 billion. The company is also changing its reporting frequency for viewership data from semi-annually to annually. Based on a valuation model using analyst estimates for future EPS growth of 15% annually and a trailing P/E ratio of 23, Netflix's stock is currently trading at a forward P/E of approximately 20 times earnings. This valuation is considered cheap for a company with Netflix's growth and return on invested capital profile. The stock is currently trading around $74.35, and the analysis suggests a potential target of $142.83, representing an upside of over 110% over the next five years. The fail bound, below which the bullish thesis would be invalidated, is estimated at $50.00.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
1 signal remains active.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
PEPSI STOCK IS CRASHING! Dividend Cut & Upside
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.
